
Jason B Kaplan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8658111/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Phase Ib study of combinations of avadomide (CCâ€122), CCâ€223, CCâ€292, and rituximab in patients with relapsed/refractory diffuse large Bâ€cell lymphoma. EJHaem, 2022, 3, 139-153.	0.4	4
2	A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomas. Leukemia and Lymphoma, 2021, 62, 3493-3500.	0.6	17
3	Activity of the Gamma Secretase Inhibitor AL101 in Desmoid Tumors: A Case Report of 2 Adult Cases. Current Oncology, 2021, 28, 3659-3667.	0.9	12
4	Survival outcomes of diffuse large B-cell lymphoma by association with concurrent or antecedent follicular lymphoma and double hit status. Leukemia and Lymphoma, 2019, 60, 3266-3271.	0.6	4
5	Progression of undiagnosed cutaneous lymphoma after anti–tumor necrosis factor-alpha therapy. Journal of the American Academy of Dermatology, 2018, 78, 1068-1076.	0.6	46
6	Hemophagocytic Lymphohistiocytosis in Cutaneous T-Cell Lymphoma. JAMA Dermatology, 2018, 154, 828.	2.0	21
7	Another tyrosine kinase inhibitor-resistance mutation within the BCR-ABL kinase domain: chasing our tails?. Leukemia and Lymphoma, 2017, 58, 1526-1527.	0.6	2
8	Nodal Signaling as a Developmental Therapeutics Target in Oncology. Molecular Cancer Therapeutics, 2017, 16, 787-792.	1.9	27
9	Meta-analysis of selected toxicity endpoints of CDK4/6 inhibitors: Palbociclib and ribociclib. Breast, 2017, 35, 1-7.	0.9	23
10	CD8 + mycosis fungoides: A low-grade lymphoproliferative disorder. Journal of the American Academy of Dermatology, 2017, 77, 489-496.	0.6	31
11	Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA. Oncotarget, 2016, 7, 65364-65373.	0.8	99
12	The challenge of developmental therapeutics for adrenocortical carcinoma. Oncotarget, 2016, 7, 46734-46749.	0.8	17
13	SNPing away to individualize induction therapy for acute myelogenous leukemia. Leukemia and Lymphoma, 2016, 57, 742-743.	0.6	0
14	Durable Responses With Maintenance Dose-Sparing Regimens of Romidepsin in Cutaneous T-Cell Lymphoma. JAMA Oncology, 2016, 2, 790.	3.4	29
15	Evolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative Neoplasms. EBioMedicine, 2016, 3, 17-25.	2.7	6
16	Adenoid cystic carcinoma: current therapy and potential therapeutic advances based on genomic profiling. Oncotarget, 2015, 6, 37117-37134.	0.8	80
17	Predicting resistance to dasatinib therapy for patients with Philadelphia-positive leukemia with prior tyrosine kinase inhibitor failure. Leukemia and Lymphoma, 2015, 56, 1922-1923.	0.6	0
18	Blinatumomab for the treatment of acute lymphoblastic leukemia. Investigational New Drugs, 2015, 33, 1271-1279.	1.2	30

ACON	D	Kaplan
IASUN	D	NAPLAN

#	Article	IF	CITATIONS
19	Targeted therapies for cutaneous T-cell lymphomas. Expert Review of Hematology, 2014, 7, 481-493.	1.0	6